Brief: Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval By NMPA China
17/01/2025 01:33
Jan 17 (Reuters) - Innovent Biologics Inc 1801.HK :
* THIRD-GENERATION EGFR TKI LIMERTINIB RECEIVED APPROVAL BY
NMPA
CHINA
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis